Source: Annual Congress 2004 - New and emerging pharmacological strategies in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Alfón, E. González, A. Motos, R. Rosa, L. A. Gómez, M. Merlos, E. Carceller, J. Cortijo, E. Morcillo (Palau-solità i Plegamans, Valencia, Spain). UR-13484, an orally active small molecule VLA-4 inhibitor that reduces lung inflammation. Eur Respir J 2004; 24: Suppl. 48, 1378

Member's Comments

No comment yet.

Related content which might interest you: SD-208 an orally active TGF-β1 receptor antagonist inhibits TGF-β1 induced progressive lung fibrosis in rat Source: Annual Congress 2003 - Animal models of lung injury: useful or not? Year: 2003 Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002 The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001 The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 Roflumilast potently inhibits CXCL1 mediated neutrophil migration in COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 Roflumilast inhibits leukocyte cell interactions in vivo Source: Eur Respir J 2006; 28: Suppl. 50, 224s Year: 2006 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 A functional variant of secretory leukocyte protease inhibitor (SLPI) with improved anti-inflammatory activity against pulmonary infection Source: Lung Science Conference 2015 Year: 2015 Dipeptide HCH6-1 inhibits neutrophil activation and protects against acute lung injury by blocking FPR1 Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells Source: Virtual Congress 2021 – Emerging respiratory diseases: state-of-the-art studies of SARS-CoV-2 infection Year: 2021 A decoy CXCL8 with increased glycosaminoglycan binding has potent anti-inflammatory activity in lung inflammation models Source: Annual Congress 2010 - Pre-clinical models of airways disease Year: 2010 PUR1800 (RV1162), A novel narrow spectrum kinase inhibitor, but not Fluticasone, reduces TNFa-induced cytokine release by primary bronchial epithelial cells from healthy volunteers and COPD patients Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001 Treatment with proteinase inhibitor, BbCI, modulates inflammatory response, mechanic alterations, and remodeling on elastase-induced emphysema in mice Source: Annual Congress 2012 - The many roads to lung injury Year: 2012 Inhibition of LPS-induced neutrophil recruitment in the lungs correlates with modulation of neutrophil CD11b expression using the selective CXCR2 receptor antagonist SB-656933 Source: Eur Respir J 2004; 24: Suppl. 48, 218s Year: 2004 N-acetyl cysteine inhibits IL-17-induced IL-8 production from human airway smooth muscle cells - a possible role for anti-oxidant treatment in chronic lung rejection? Source: Eur Respir J 2003; 22: Suppl. 45, 202s Year: 2003 No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Role of alveolar epithelial ICAM-1 in lipopolysaccharide-induced lung inflammation Source: Eur Respir J 2002; 19: 1142-1150 Year: 2002